Advertisement
Loading...

Evolus, Inc.

EOLSNASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$6.50
$-0.08(-1.22%)
U.S. Market opens in 28h 25m

Evolus, Inc. (EOLS) Stock Overview

Explore Evolus, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap428.1M
P/E Ratio-9.80
EPS (TTM)$-0.66
ROE1.75%
Fundamental Analysis

AI Price Forecasts

1 Month$4.78
3 Months$0.00
1 Year Target$0.00

EOLS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Evolus, Inc. (EOLS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 72.53, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -9.80 and a market capitalization of 428.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-1.22%
5-Day Change
2.69%
1-Month Change
40.39%
3-Month Change
51.16%
6-Month Change
-9.97%
Year-to-Date (YTD) Change
-2.26%
1-Year Change
-35.00%
3-Year Change
-37.02%
5-Year Change
-27.37%
All-Time (Max) Change
-43.48%

Contact Information

949 284 4555
520 Newport Center Drive, Newport Beach, CA, 92660

Company Facts

372 Employees
IPO DateFeb 8, 2018
CountryUS
Actively Trading

Frequently Asked Questions